The IndexBox report highlights significant developments in the global Live Biotherapeutic Products (LBP) CDMO market, projecting robust growth from 2026 to 2035 as demand surges due to the transition of microbiome drug candidates into late-stage trials. Key drivers include increased pharmaceutical outsourcing, scientific validation of microbiome’s role in diseases, and advancements in manufacturing technologies. The market faces challenges such as high capital intensity and evolving regulations. It will see a segmentation between broad-platform providers and niche specialists, with demand particularly strong in gastrointestinal disorders (35% market share) and oncology (25%). North America dominates the market, followed by Europe and a rapidly growing Asia-Pacific region. Overall, a compound annual growth rate of 12% is expected, indicating a promising future for the sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/live-biotherapeutic-products-microbiome-cdmo-market-driven-by-over-150-advancing-clinical-programs-to-2035/
